Singapore Institute of Advanced Medicine Holdings looks to drive
proton therapy patient flow as it enters into a medical services
agreement with Icon Singapore, enhancing treatment options and
access for cancer patients
- Incremental Business: Provision of proton therapy treatment to Icon’s patients
may increase patient flow and revenue for PTPL. This collaboration will increase
treatment options and enhance access for Icon’s cancer patients. - Long-Term Agreement: The agreement will be valid for an initial term of 3 years
commencing from 1 July 2024, thereby ensuring a steady flow of patients in the long run.
Singapore, 26 June 2024 – Singapore Institute of Advanced Medicine Holdings Ltd. (“SAM Holdings” or the “Company”, and together with its subsidiaries, the “Group”), has on 26 June 2024 entered into a medical services agreement with Icon SOC Pte. Ltd. (“Icon”) through its wholly-owned subsidiary Proton Therapy Pte. Ltd. (“PTPL”) for the provision of proton therapy treatment medical services to Icon’s patients.
This collaboration amalgamates PTPL’s know-how and core capabilities in proton therapy with Icon’s deep expertise and network in oncology. It enables PTPL access to Icon’s wider patient network while enhancing the provision of comprehensive cancer care at Icon through the addition of PTPL’s proton therapy capabilities. The term of the agreement will commence from 1 July 2024 for an initial term of 3 years.
Icon is primarily engaged in the business of provision of medical and radiation oncology
services. It is a part of the Icon Group – Australia’s largest dedicated provider of cancer care. Today, Icon Group delivers over 3.5 million patient interactions across more than 50 cancer centres, five compounding facilities and the management of 70 plus pharmacies.
Commenting on the medical services agreement, Dr Djeng Shih Kien, Executive Director and CEO, and founder, of SAM Holdings, said, “The partnership underlines what we had envisioned when we set out on this journey to improve the quality of life of cancer patients. We are excited to partner with Icon Singapore as it allows us to enhance our reach and impact the life of many more cancer patients throughout the region.”
“At Icon, the patient is at the heart of everything we do. This collaboration marks our commitment to provide new and novel treatment options for our patients, enhancing our current suite of best-in-class cancer treatments and technologies.” said Serena Wee, Chief Executive Officer of Icon ASEAN and Hong Kong.
